BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17925410)

  • 1. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.
    Shorr AF; Jackson WL; Sherner JH; Moores LK
    Chest; 2008 Jan; 133(1):149-55. PubMed ID: 17925410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
    Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
    J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
    Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
    J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
    Kase CS; Albers GW; Bladin C; Fieschi C; Gabbai AA; O'Riordan W; Pineo GF;
    Stroke; 2009 Nov; 40(11):3532-40. PubMed ID: 19696423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic.
    O'Carroll CB; Capampangan DJ; Aguilar MI; Bravo TP; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
    Neurologist; 2011 Jul; 17(4):232-5. PubMed ID: 21712672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor.
    Algattas H; Damania D; DeAndrea-Lazarus I; Kimmell KT; Marko NF; Walter KA; Vates GE; Jahromi BS
    Neurosurgery; 2018 Feb; 82(2):142-154. PubMed ID: 28402497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
    Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
    Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.